Nirvana Life Sciences Inc.
NIRVX
CNSX
| 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 35.38% | 21.06% | 40.96% | 59.70% | 56.35% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -82.63% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 0.55% | -370.64% | -276.16% | -146.63% | -97.03% |
| Change in Net Operating Assets | -336.87% | -300.69% | -281.89% | -24.43% | 162.54% |
| Cash from Operations | -395.12% | -2,634.57% | -1,261.61% | -18.54% | 18.06% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 56.69% | 263.23% | 510.98% | 453.55% | 1,052.63% |
| Total Debt Repaid | 71.60% | 71.60% | 71.60% | -- | 200.00% |
| Issuance of Common Stock | -- | -- | 3,700.00% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -95.60% | -108.79% | -108.79% | -- | 200.00% |
| Cash from Financing | 1,212.77% | 2,321.21% | 2,223.72% | 28.10% | -65.28% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -205.54% | 175.22% | 40.91% | -- | -- |
| Net Change in Cash | 181.33% | 121.62% | 96.47% | 106.76% | -1,775.00% |